Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: zurdo who wrote (4240)	7/11/1998 10:24:00 AM
From: BigKNY3	Respond to of 9523

Big Pharma Report: 7/11/98 -Big Pharma increased 1.8% this week as compared to the Dow gain of 0.9% and NASDAQ jump of 2.6%. -Spurred by a strong earnings report and record breaking Viagra sales ($411M in a quarter), PFE (117.81) led Big Pharma this week with a 9.6% jump. -AHP (-4.6%) was the Big Pharma bow-wow of the week. - YTD, Big Pharma is still very healthy (+30.5%) doubling the Dow (+15.1%). -In the YTD race, the Big Three held their positions with #1 WLA (+79.5%) followed by SGP (+58.4%) and PFE (+58%). -LLY's growth (-5.7%) is still hasta Evista and remains this year's bow-wow. J & J, a Motley Fool DRIP preference over PFE, is ranked #12 at 9.1%. Having PFun! BigKNY3 _________________________________________________________ Big Pharma Report- 7/11/98 Analyst Reports You Can Use Thanks to Anthony Wong of the SI PFer Board for the following analysis. Summary of analyst ratings issued on 7/10/98. Note: 1) Target price - for 12 months, per share basis. 2) All are reiterations of old ratings, no upgrades or downgrrades.: -''buy'' by analyst Christina Heuer at Salomon Smith Barney, target price $155.00 -''strong buy'' by analyst David F. Saks at Gruntal & Co., target price $148.00 "Viagra sales will approach $1 billion this year and possibly $8 billion at peak (2005)....PFE just blew us out of the water." -''buy'' by analyst Cynthia A. Beach at Gerard Klauer Mattison, target price $140.00 -''buy'' by analyst Jerome R. Brimeyer at Warburg Dillon Read Inc target price $135.00 '-'buy'' by analyst Leonard S. Yaffe Md at NationsBanc Montgomery Sec., target price $132.00 -''buy'' by analyst Carl J. Seiden at J.P. Morgan Securities, target price $131.00 "PFE is best in industry". -near-term and long-term ''buy'' by analyst Steven C. Tighe at Merrill Lynch, no target price provided -''buy'' by analyst Kenneth R. Nover at A.G. Edwards, no target price provided -''attractive'' by analyst Jeffrey Chaffkin at PaineWebber Inc. target price $130.00 -''outperform'' by analyst Jami Rubin at Schroder & Co. , target price $130.00 -''outperform'' by analyst Paul A. Brooke at Morgan Stanley Dean Witter., target price $120.00 Source: BigKNY3 and Andrew Bary, Barrons 7/03/98: Summary of PFE recommendation issued 7/7/98 -"Hold lowered from Buy"- James Flynn, Furman Selz (PFE@111)-No target price provided. "Consider our present peak Viagra estimate of $2 billion (2002) to be potentially high".